Wu RC, Feng Q, Lonard DM, O'Malley BW (2007) SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell 129, 1125-40 17574025

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S505-p - SRC-3 (human) ▲

Modsite: SPVAGVHsPMAsSGN SwissProt Entrez-Gene Orthologous residues SRC‑3 (human): S505‑p, SRC‑3 iso2 (human): S505‑p, SRC‑3 (mouse): S498‑p, SRC‑3 (rat): S205‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3A (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, transfection of inactive enzyme Comments:  S509 is a priming site for phosphorylation of S505 Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes Akt1 (human) decrease lithium decrease estradiol increase EGF decrease PD98059 EGF inhibit treatment-induced decrease insulin decrease LY294002 insulin inhibit treatment-induced decrease Downstream Regulation Effect of modification (function):  activity, induced, molecular association, regulation, protein degradation, ubiquitination Effect of modification (process):  signaling pathway regulation, transcription, induced Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays ER-alpha (human) Induces activity, induced co-immunoprecipitation Comments:  induces ubiquitination, degradation of SRC-3, and its interaction with ER.

S509-p - SRC-3 (human) ▲

Modsite: GVHsPMAsSGNTGNH SwissProt Entrez-Gene Orthologous residues SRC‑3 (human): S509‑p, SRC‑3 iso2 (human): S509‑p, SRC‑3 (mouse): P502‑p, SRC‑3 (rat): S209‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3A (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, transfection of inactive enzyme Comments:  S509 is a priming site for phosphorylation of S505 Downstream Regulation Effect of modification (function):  activity, induced, molecular association, regulation, phosphorylation, protein degradation, ubiquitination Effect of modification (process):  signaling pathway regulation, transcription, induced Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays ER-alpha (human) Induces activity, induced co-immunoprecipitation Comments:  induces ubiquitination, degradation of SRC-3, and its interaction with ER., S509 is a priming site for phosphorylation of S505

K723-ub - SRC-3 (human) ▲

Modsite: CGDGNVVkQEQLsPK SwissProt Entrez-Gene Orthologous residues SRC‑3 (human): K723‑ub, SRC‑3 iso2 (human): K723‑ub, SRC‑3 (mouse): R715‑ub, SRC‑3 (rat): X422‑ub Characterization Methods used to characterize site in vivo:  mutation of modification site, western blotting Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE FBXW7 (human) Downstream Regulation Effect of modification (function):  activity, induced, molecular association, regulation, protein degradation, ubiquitination Effect of modification (process):  signaling pathway regulation, transcription, induced Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays ER-alpha (human) Induces activity, induced co-immunoprecipitation Comments:  induces ubiquitination, degradation of SRC-3, and its interaction with ER.

K786-ub - SRC-3 (human) ▲

Modsite: QEKDPKIkTETSEEG SwissProt Entrez-Gene Orthologous residues SRC‑3 (human): K786‑ub, SRC‑3 iso2 (human): K786‑ub, SRC‑3 (mouse): K778‑ub, SRC‑3 (rat): K485‑ub Characterization Methods used to characterize site in vivo:  mutation of modification site, western blotting Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE FBXW7 (human) Downstream Regulation Effect of modification (function):  activity, induced, molecular association, regulation, protein degradation, ubiquitination Effect of modification (process):  signaling pathway regulation, transcription, induced Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays ER-alpha (human) Induces activity, induced co-immunoprecipitation Comments:  induces ubiquitination, degradation of SRC-3, and its interaction with ER.